CoChat

Preferential in vivo action of F15599, a novel 5‐HT1Areceptor agonist, at postsynaptic 5‐HT1Areceptors

Open access
Lladó‐Pelfort, L, Assié, M‐B, Newman‐Tancredi, A, Artigas, F, Celada, P · 2010 · British Journal of Pharmacology
Cited by 103

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background and purpose: F15599, a novel 5‐hydroxytryptamine (5‐HT)1A receptor agonist with 1000‐fold selectivity for 5‐HT compared with other monoamine receptors, shows antidepressant and procognitive activity at very low doses in animal models. We examined the in vivo activity of F15599 at somatodendritic autoreceptors and postsynaptic 5‐HT 1A heteroreceptors. Experimental approach: In vivo single unit and local field potential recordings and microdialysis in the rat. Key results: F15599 increased the discharge rate of pyramidal neurones in medial prefrontal cortex (mPFC) from 0.2 µg·kg−1 i.v and reduced that of dorsal raphe 5‐hydroxytryptaminergic neurones at doses >10‐fold higher (minimal effective dose 8.2 µg·kg−1 i.v.). Both effects were reversed by the 5‐HT 1A antagonist (±)WAY100635. F15599 did not alter low frequency oscillations (∼1 Hz) in mPFC. In microdialysis studies, F15599 increased dopamine output in mPFC (an effect dependent on the activation of postsynaptic 5‐HT 1A receptors) with an ED 50 of 30 µg·kg−1 i.p., whereas it reduced hippocampal 5‐HT release (an effect dependent exclusively on 5‐HT 1A autoreceptor activation) with an ED 50 of 240 µg·kg−1 i.p. Likewise, application of F15599 by reverse dialysis in mPFC increased dopamine output in a concentration‐dependent manner. All neurochemical responses to F15599 were prevented by administration of (±)WAY100635. Conclusions and implications: These results indicate that systemic administration of F15599 preferentially activates postsynaptic 5‐HT 1A receptors in PFC rather than somatodendritic 5‐HT 1A autoreceptors. This regional selectivity distinguishes F15599 from previously developed 5‐HT 1A receptor agonists, which preferentially activate somatodendritic 5‐HT 1A autoreceptors, suggesting that F15599 may be particularly useful in the treatment of depression and of cognitive deficits in schizophrenia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2010.00738.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 103

Metadata

Authors
Lladó‐Pelfort, L., Assié, M., Newman‐Tancredi, A., Artigas, F., & Celada, P.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2010-03-08
Volume
160
Issue
8
Pages
1929-1940
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1588173517
Cited by
103
References
8
FWCI
3.28
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preferential in vivo action of F15599, a novel 5‐HT1Areceptor agonist, at postsynaptic 5‐HT1Areceptors. https://app.cochat.ai/papers/10.1111/j.1476-5381.2010.00738.x
The paper
Lladó‐Pelfort, L., Assié, M., Newman‐Tancredi, A., Artigas, F., & Celada, P. (2010). Preferential in vivo action of F15599, a novel 5‐HT1Areceptor agonist, at postsynaptic 5‐HT1Areceptors. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2010.00738.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.